Prize4Life was excited to participate in the Drug Company Working Group Meeting sponsored by the ALS Association at the 2014 American Academy of Neurology Annual Meeting in Philadelphia. The meeting of over 60 attendees from industry, academia and government, was full of stimulating discussions surrounding cutting edge research and drug development findings in ALS. Nicholas Maragakis, M.D., from Johns Hopkins University gave an update on applications of induced pluripotent stem cells (iPSC) in ALS research, and Robert Baloh, M.D., Ph.D., of Cedars-Sinai Medical Center in Los Angeles shared the latest insights on the role of C9orf72, and how the known mutations cause ALS. On the clinical development side, Shafeeq Lahda, M.D., from the Barrow Neurological Institute in Phoenix laid out the pilot clinical trial he is leading of an anti-inflammatory arthritis treatment in ALS. The presentations concluded with much-awaited discussion by Andrew Wolff, M.D., Chief Medical Officer of Cytokinetics, about the mixed results of the Phase II trial of tirasemtiv in ALS. To read the full report from the ALS Association, click here.
conf-american-academy-of-neurology-annual-meeting cytokinetics disease-als drug company working group meeting topic-clinical topic-preclinical topic-randdShare this: